Literature DB >> 16297667

BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells.

Artur Slupianek1, Michal O Nowicki, Mateusz Koptyra, Tomasz Skorski.   

Abstract

The oncogenic BCR/ABL tyrosine kinase facilitates the repair of DNA double-strand breaks (DSBs). We find that after gamma-irradiation BCR/ABL-positive leukemia cells accumulate more DSBs in comparison to normal cells. These lesions are efficiently repaired in a time-dependent fashion by BCR/ABL-stimulated non-homologous end-joining (NHEJ) followed by homologous recombination repair (HRR) mechanisms. However, mutations and large deletions were detected in HRR and NHEJ products, respectively, in BCR/ABL-positive leukemia cells. We propose that unfaithful repair of DSBs may contribute to genomic instability in the Philadelphia chromosome-positive leukemias.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297667      PMCID: PMC2856314          DOI: 10.1016/j.dnarep.2005.10.005

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  52 in total

1.  Domain structure, localization, and function of DNA polymerase eta, defective in xeroderma pigmentosum variant cells.

Authors:  P Kannouche; B C Broughton; M Volker; F Hanaoka; L H Mullenders; A R Lehmann
Journal:  Genes Dev       Date:  2001-01-15       Impact factor: 11.361

2.  Low fidelity DNA synthesis by human DNA polymerase-eta.

Authors:  T Matsuda; K Bebenek; C Masutani; F Hanaoka; T A Kunkel
Journal:  Nature       Date:  2000-04-27       Impact factor: 49.962

3.  XRCC3 promotes homology-directed repair of DNA damage in mammalian cells.

Authors:  A J Pierce; R D Johnson; L H Thompson; M Jasin
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

4.  Efficient rejoining of radiation-induced DNA double-strand breaks in vertebrate cells deficient in genes of the RAD52 epistasis group.

Authors:  H Wang; Z C Zeng; T A Bui; E Sonoda; M Takata; S Takeda; G Iliakis
Journal:  Oncogene       Date:  2001-04-26       Impact factor: 9.867

5.  The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.

Authors:  M Sattler; S Verma; G Shrikhande; C H Byrne; Y B Pride; T Winkler; E A Greenfield; R Salgia; J D Griffin
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

Review 6.  Reproductive toxins: pervasive theme of oxidative stress and electron transfer.

Authors:  P Kovacic; J D Jacintho
Journal:  Curr Med Chem       Date:  2001-06       Impact factor: 4.530

7.  BCR-ABL down-regulates the DNA repair protein DNA-PKcs.

Authors:  E Deutsch; A Dugray; B AbdulKarim; E Marangoni; L Maggiorella; S Vaganay; R M'Kacher; S D Rasy; F Eschwege; W Vainchenker; A G Turhan; J Bourhis
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

8.  A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage.

Authors:  T T Paull; E P Rogakou; V Yamazaki; C U Kirchgessner; M Gellert; W M Bonner
Journal:  Curr Biol       Date:  2000 Jul 27-Aug 10       Impact factor: 10.834

9.  Preferential incorporation of G opposite template T by the low-fidelity human DNA polymerase iota.

Authors:  Y Zhang; F Yuan; X Wu; Z Wang
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

10.  Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase.

Authors:  H F Salloukh; P Laneuville
Journal:  Leukemia       Date:  2000-08       Impact factor: 11.528

View more
  30 in total

1.  IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.

Authors:  Silvia Maifrede; Kayla Martin; Paulina Podszywalow-Bartnicka; Katherine Sullivan-Reed; Samantha K Langer; Reza Nejati; Yashodhara Dasgupta; Michael Hulse; Daniel Gritsyuk; Margaret Nieborowska-Skorska; Lena N Lupey-Green; Huaqing Zhao; Katarzyna Piwocka; Mariusz A Wasik; Italo Tempera; Tomasz Skorski
Journal:  Mol Cancer Res       Date:  2017-06-20       Impact factor: 5.852

2.  BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.

Authors:  M Koptyra; K Cramer; A Slupianek; C Richardson; T Skorski
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

3.  BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.

Authors:  Mirle Schemionek; Christian Elling; Ulrich Steidl; Nicole Bäumer; Ashley Hamilton; Tilmann Spieker; Joachim R Göthert; Martin Stehling; Amy Wagers; Claudia S Huettner; Daniel G Tenen; Lara Tickenbrock; Wolfgang E Berdel; Hubert Serve; Tessa L Holyoake; Carsten Müller-Tidow; Steffen Koschmieder
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

4.  Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.

Authors:  Tariq I Mughal; Jerald P Radich; Richard A Van Etten; Alfonso Quintás-Cardama; Tomasz Skorski; Farhad Ravandi; Daniel J DeAngelo; Carlo Gambacorti-Passerini; Giovanni Martinelli; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2011-09       Impact factor: 10.047

Review 5.  BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

Authors:  B A Burke; M Carroll
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

6.  Emerging Roles of SIRT1 in Cancer Drug Resistance.

Authors:  Zhiqiang Wang; Wenyong Chen
Journal:  Genes Cancer       Date:  2013-03

Review 7.  Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Authors:  Melanie T Rebechi; Keith W Pratz
Journal:  Leuk Lymphoma       Date:  2017-02-06

8.  BCR/ABL stimulates WRN to promote survival and genomic instability.

Authors:  Artur Slupianek; Tomasz Poplawski; Stanislaw K Jozwiakowski; Kimberly Cramer; Dariusz Pytel; Ewelina Stoczynska; Michal O Nowicki; Janusz Blasiak; Tomasz Skorski
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

9.  Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.

Authors:  Tom Lenaerts; Jorge M Pacheco; Arne Traulsen; David Dingli
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

Review 10.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.